Tamtam Try Tamtam free
Bristol Myers Squibb logo

Bristol Myers Squibb account plan

Transforming patients' lives through science

At a glance

Bristol-Myers Squibb is a Princeton, NJ biopharmaceutical company with FY2025 revenues of $48,194 million and about 32,500 employees.

Bristol-Myers Squibb (BMS) discovers, develops, manufactures and sells medicines in oncology, hematology, immunology, cardiovascular and neuroscience, operating as a single segment. It sells mainly through wholesalers, distributors and specialty pharmacies; the United States made up 69% of FY2025 revenues and International 29%. FY2025 total revenues were $48,194 million (2024: $48,300 million), with net earnings attributable to BMS of $7,054 million. It had approximately 32,500 employees in 43 countries at December 31, 2025, and manufactures in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.

Business units

Strategic priorities

Grow through the loss-of-exclusivity period
Revlimid and Pomalyst face generics in the U.S., Eliquis EU patents expire in November 2026 and its U.S. LOE is April 2028; management still expects a $1.5 billion to $2 billion Eliquis step down in 2027.
Launch the next wave of medicines
Over 45 unique assets are in development; the CEO sees the potential for more than 10 new medicines by the end of the decade. Iberdomide (PDUFA August 17, 2026) and mezigdomide (PDUFA May 13, 2027) aim to replace Revlimid and Pomalyst in second line.
AI across R&D and the enterprise
BMS expanded its NVIDIA collaboration in July 2026 and agreed in May 2026 to deploy Claude from Anthropic across research, clinical development, manufacturing, commercial and corporate functions. The CEO believes AI can take two to three years off development.
Strategic productivity initiative
The initiative is expected to deliver annual cost savings of approximately $2.0 billion by the end of 2027.
Disciplined capital allocation
Business development remains a top allocation priority alongside debt reduction: net debt fell to $31,656 million at June 30, 2026 from $34,043 million at December 31, 2025.

Latest results

In Q2 2026 total revenues rose 6% to $12,973 million (H1 2026: $24,462 million, +4%). The Growth Portfolio grew 15% to $7,560 million, led by Opdivo Qvantig, Reblozyl, Camzyos and Breyanzi, while the Legacy Portfolio fell 4% as Eliquis (+22%) only partly offset Revlimid (-49%) and Pomalyst/Imnovid (-71%). GAAP EPS was $1.62 and non-GAAP EPS $2.04 (Q2 2025: $0.64 and $1.46). In July 2026 BMS raised 2026 revenue guidance to approximately $49.0 billion to $50.0 billion (from $46.0 billion to $47.5 billion) and non-GAAP EPS guidance to $6.75 - $7.00.

Investments and deals

Hengrui collaboration
May 2026 agreement on 13 early-stage assets in oncology, hematology and immunology: $600 million upfront and up to $14.3 billion of milestones plus royalties.
2025 deals
Orbital Therapeutics acquisition (in vivo CAR-T), BioNTech collaboration on pumitamig ($1,500 million upfront) and a Philochem licence for a prostate cancer radiopharmaceutical.
Manufacturing and R&D capex
Capex of approximately $1.3 billion expected in 2026 for cell therapy and other manufacturing, R&D and additional U.S. domestic manufacturing; a new R&D facility in San Diego is planned for 2026.
Divestment in China
Sale of the 60% stake in Sino-American Shanghai Squibb Pharmaceuticals for $164 million of net cash proceeds and a $109 million gain.

Challenges and risks

Generic erosion
Revlimid licences are no longer volume-limited from January 31, 2026, Pomalyst has U.S. generics since March 2026, and Eliquis generics may launch in the U.S. in 2028.
U.S. pricing pressure
IRA maximum fair prices apply to Eliquis from January 1, 2026, Pomalyst from 2027 and Orencia from 2028; the December 2025 U.S. Government Agreement includes free Eliquis to Medicaid.
Pipeline setbacks
ODYSSEY-HCM missed its endpoints, the Cobenfy ARISE trial missed its primary endpoint, the milvexian ACS trial was stopped in November 2025 and its atrial fibrillation readout moved to Q1 2027.
Declining royalties and debt
Keytruda and Tecentriq royalties are expected to end on December 31, 2026, and the 10-K lists significant indebtedness among its risks.
Access to patients
Cobenfy access is limited because, per the CEO, half of U.S. counties lack a practicing psychiatrist.

What leadership says

“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business.”

Christopher Boerner, Board Chair and Chief Executive Officer · Q2 2026 results release, July 30, 2026

“We certainly don't feel any compulsion to chase deals”

Christopher Boerner, Board Chair and Chief Executive Officer · Q2 2026 earnings call, July 30, 2026

“Our goal is to make iber and mezi foundational in multiple myeloma, replacing Rev and Pom in second line over time.”

Adam Lenkowsky, Chief Commercialization Officer · Q2 2026 earnings call, July 30, 2026

“We've already proven, for example, that you can take months off the time needed to write regulatory documents, using this technology.”

Chris Boerner, Chair of the Board and Chief Executive Officer · Fortune interview, December 5, 2025

Where a supplier can help

AI and data tooling for R&D
Tied to the AI priority: BMS is putting AI across R&D and corporate functions, so suppliers of data, clinical trial optimisation or document automation tools fit the stated aim of shortening development.
Launch readiness for new medicines
Tied to the launch priority: iberdomide, mezigdomide and other filings create demand for commercial, medical and patient-access services, with SG&A rising for new product launches.
Cost savings programmes
Tied to the productivity initiative: a target of approximately $2.0 billion of savings by the end of 2027 favours suppliers who can show measurable cost reduction.
Manufacturing and cell therapy capacity
Tied to the approximately $1.3 billion 2026 capex for cell therapy, U.S. domestic manufacturing and the San Diego R&D facility.
Patient access in underserved areas
Tied to the access challenge: digital and outreach tools that reach patients without a local psychiatrist would support Cobenfy uptake.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Bristol Myers Squibb?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Bristol Myers Squibb

What does Bristol-Myers Squibb do?

BMS is a biopharmaceutical company that discovers, develops and sells medicines in oncology, hematology, immunology, cardiovascular and neuroscience. Its largest products include Eliquis and Opdivo.

What is Bristol-Myers Squibb's revenue?

FY2025 total revenues were $48,194 million. In July 2026 it guided 2026 revenues to approximately $49.0 billion to $50.0 billion.

How many employees does Bristol-Myers Squibb have?

Approximately 32,500 employees in 43 countries at December 31, 2025, about 54% in the U.S.

Who leads Bristol-Myers Squibb?

Christopher Boerner is Chair of the Board and Chief Executive Officer; David Elkins is EVP and CFO.

What is Bristol-Myers Squibb's strategy?

To grow the Growth Portfolio and launch new medicines through the Eliquis, Revlimid and Pomalyst losses of exclusivity, while cutting approximately $2.0 billion of costs by the end of 2027 and using AI across R&D.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)